Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 464 across all filing types
Latest filing 2019-11-27 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Corrigendum
Regulatory Filings
2019-11-27 English
Updates
M&A Activity Classification · 95% confidence The document is titled 'Letter of Offer (LOO)' and is addressed to eligible equity shareholders of Lasa Supergenerics Limited. It details an open offer by an acquirer to purchase shares, referencing the Securities and Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The content includes offer price, number of shares, schedule of activities related to the offer, risk factors, and regulatory compliance details. This is characteristic of a takeover or acquisition offer document, specifically a Letter of Offer under SEBI regulations, which is a formal document issued in the context of mergers and acquisitions or substantial acquisition of shares. Therefore, the document fits the category of M&A Activity (TAR) filings, which include announcements and documents related to merger proposals or takeover bids.
2019-11-25 English
Updates
Regulatory Filings
2019-11-15 English
Financial Result Updates
Regulatory Filings
2019-11-13 English
Outcome of Board Meeting
Regulatory Filings
2019-11-12 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of a scheduled Board Meeting to consider and approve unaudited financial results for the quarter/half year ended September 30, 2019. It also mentions the closure of the trading window in compliance with insider trading regulations. The document is short (2185 characters) and serves as an intimation or announcement rather than containing the actual financial results or detailed report. It does not include financial statements or substantive financial data but rather informs about the upcoming board meeting and related compliance matters. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into other specific categories like Interim Report or Earnings Release.
2019-11-04 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.